Dive into the archives.


  • Quebec willing to test MS treatment

    A call for a national trial of a controversial M-S treatment has gained support. Quebec Health Minister Yves Bolduc says the province would be willing to join a national clinical trial of the so-called liberation procedure. The treatment is based on an unproven theory that blocked veins in the neck or spinal cord are to [...]

  • ‘Placebo effect’ a concern with CCSVI

    Canadians experts say they fear stories of miraculous results from a controversial new MS treatment could be more about the “placebo effect” than an actual breakthrough — fears given new credence by two discouraging new European studies. “I appreciate what people are going through — living with MS can be a terrible thing and they [...]

  • New research fails to support CCSVI theory

    THURSDAY, Aug. 5 (HealthDay News) — An emerging hypothesis suggests that the demyelination of cerebral veins that characterizes multiple sclerosis (MS) may be caused by chronic cerebrospinal venous insufficiency (CCSVI), but research published in the August issue of the Annals of Neurology does not concur with the hypothesis. Peter Sundström, M.D., of Umea University in [...]

  • University of Buffalo to Conduct CCSVI Trial

    BUFFALO, N.Y. — Buffalo medical researchers led by a team from the University at Buffalo Department of Neurosurgery, will embark on a landmark prospective randomized double-blinded study to test the safety and efficacy of interventional endovascular therapy –dubbed “liberation treatment” — on the symptoms and progression of Multiple Sclerosis (MS). Recent research has strongly associated [...]

  • A New Cause for MS?

    By Henry L. Davis NEWS MEDICAL REPORTER October 15, 2009, 6:36 AM Buffalo physicians announced Wednesday that they have started a large study that could overturn thinking about the generally accepted cause for multiple sclerosis. MS is believed to stem from an abnormal response of the body’s immune system directed against the fatty sheath that [...]

TAG / CLOUD

AAN, alemtuzumab, Avonex, Bayer, Betaseron, Biogen, BioMS Medical Corp, CCSVI, CIS, Cladribine, CLARITY, cognitive dysfunction, Copaxone, daclizumab, dirucotide, discovery, EAE, ECTRIMS, Elan, Fampridine-SR, FDA, FDA fast track status, fingolimod, FTY-720, Gilenia, interferons, laquinimod, Marijuana, Merck, Merck/Serono, Novartis, Oral MS Therapies, Phase III, PML, Rebif, remyelination, RRMS, side effects, smoking, SPMS, stem cells, Teriflunomide, Teva, therapy, Tysabri

Archives



Follow me on Twitter
Fave this on Technorati


Bookmark and Share


Wordpress Engine. Upstart Theme. Better Project.